| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 30.93 mm | 30.93 mm | 30.93 mm | 30.93 mm | 30.93 mm | 30.93 mm |
| Cash burn (monthly) | (no burn) | 4.13 mm | 6.45 mm | 8.24 mm | 6.16 mm | 6.75 mm |
| Cash used (since last report) | n/a | 9.65 mm | 15.09 mm | 19.28 mm | 14.41 mm | 15.79 mm |
| Cash remaining | n/a | 21.28 mm | 15.84 mm | 11.65 mm | 16.53 mm | 15.15 mm |
| Runway (months of cash) | n/a | 5.2 | 2.5 | 1.4 | 2.7 | 2.2 |
| 13F holders | Current |
|---|---|
| Total holders | 13 |
| Opened positions | 3 |
| Closed positions | 15 |
| Increased positions | 0 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 11.17 bn |
| Total shares | 56.89 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Lundbeckfond Invest A/S | 21.85 mm | $39.33 mm |
| Kurma Partners | 12.25 mm | $22.55 mm |
| Vivo Capital | 6.17 mm | $6.48 bn |
| HBM Healthcare Investments | 5.52 mm | $9.94 mm |
| Samsara BioCapital | 3.64 mm | $6.55 mm |
| Novo Holdings A/S | 3.35 mm | $3.52 bn |
| Vivo Capital IX | 3.02 mm | $40.17 mm |
| Pivotal bioVenture Partners Investment Advisor | 864.20 k | $907.41 mm |
| Renaissance Technologies | 97.00 k | $101.85 mm |
| Acadian Asset Management | 60.65 k | $63.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Jun 25 | Collins Helen Louise | Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 35,144 | 52.72 k | 35,144 |
| 5 Jun 25 | Christian E Elling | Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 35,144 | 52.72 k | 35,144 |
| 5 Jun 25 | Heidi Hunter | Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 35,144 | 52.72 k | 35,144 |
| 5 Jun 25 | Peter Hirth | Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 35,144 | 52.72 k | 35,144 |
| 5 Jun 25 | Kathleen Sereda Glaub | Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 35,144 | 52.72 k | 35,144 |
